Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter

被引:192
作者
Wu, XC [1 ]
Whitfield, LR [1 ]
Stewart, BH [1 ]
机构
[1] Warner Lambert Co, Parke Davis Pharmaceut Res, Dept Pharmacokinet Dynam & Metab, Ann Arbor, MI USA
关键词
atorvastatin; Caco-2; P-glycoprotein; monocarboxylic acid transporter;
D O I
10.1023/A:1007525616017
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Purpose. The purpose of this study was to elucidate the mechanisms by which an HMG-CoA reductase inhibitor, atorvastatin (an organic acid with a pKa of 4.46), was transported in the secretory and absorptive directions across Caco-2 cell monolayers. Methods. Caco-2 cells were grown on polycarbonate membrane inserts in 6-well Snapwell plates (Costar). The permeability of radiolabeled compounds across Caco-2 cell monolayers was determined using a side-by-side diffusion apparatus (NaviCyte) and an automated liquid handler (Hamilton Microlab 2200). The apical uptake of C-14-atorvastatin was also determined in Caco-2 cells. Cyclosporin A (20 mu M) was present in the uptake media to block potential P-glycoprotein-mediated atorvastatin efflux. Results. Polarized permeation of atorvastatin was observed with the basolateral-to-apical (B-to-A) permeability being 7-fold greater than the A-to-B permeability (35.6 x 10(-6) and 4.9 x 10(-6) cm/s, respectively). The secretion of atorvastatin was a saturable process with an apparent K-m of 115 mu M. The B-to-A permeability of atorvastatin was significantly reduced by cyclosporin A (10 mu M), verapamil (100 mu M), and a P-glycoprotein specific monoclonal antibody, UIC2(10 mu g/ml) (43%, 25%, and 13%, respectively). Furthermore, both CsA and verapamil significantly increased the A-to-B permeability of atorvastatin by 60%; however, UIC2 did not affect the A-to-B permeability of atorvastatin. CsA uncompetitively inhibited the B-to-A flux of atorvastatin with a K-i of 5 mu M In addition, atorvastatin (100 mu M) significantly inhibited the B-to-A permeability of vinblastine by 61%. The apical uptake of atorvastatin increased 10.5-fold when the apical pH decreased from pH 7.4 to pH 5.5 while the pH in the basolateral side was fixed at pH 7.4. A proton ionophore, carbonylcyanide p-trifluoro-methoxyphenylhydrazone (FCCP) significantly decreased atorvastatin uptake. Tn addition, atorvastatin uptake was significantly inhibited by benzoic acid, nicotinic acid, and acetic acid each at 20 mM (65%, 14%, and 40%, respectively). Benzoic acid competitively inhibited atorvastatin uptake with a K-i of 14 mM. Similarly, benzoic acid, nicotinic acid, and acetic acid significantly, inhibited the A-to-B permeability of atorvastatin by 71%, 21%, and 66%, respectively. Conclusion. This study demonstrated that atorvastatin was secreted across the apical surface of Caco-2 cell monolayers via P-glycoprotein-mediated efflux and transported across the apical membrane in the absorptive direction via a H+-monocarboxylic acid cotransporter (MCT). In addition, this study provided the first evidence that negatively charged compounds, such as atorvastatin, can be a substrate for P-glycoprotein.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 15 条
[1]
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects [J].
Cilla, DD ;
Whitfield, LR ;
Gibson, DM ;
Sedman, AJ ;
Posvar, EL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) :687-695
[2]
HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells [J].
Dimitroulakos, J ;
Yeger, H .
NATURE MEDICINE, 1996, 2 (03) :326-333
[3]
Dixon M., 1979, ENZYMES, P332
[4]
Gibson Donald M., 1997, Pharmaceutical Research (New York), V14, pS253
[5]
Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake [J].
Gutmann, H ;
Fricker, G ;
Török, M ;
Michael, S ;
Beglinger, C ;
Drewe, J .
PHARMACEUTICAL RESEARCH, 1999, 16 (03) :402-407
[6]
HUNTER J, 1993, J BIOL CHEM, V268, P14991
[7]
EFFICIENT INHIBITION OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE WITH A MONOCLONAL-ANTIBODY [J].
MECHETNER, EB ;
RONINSON, IB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (13) :5824-5828
[8]
MICHNIEWICZ BM, 1994, ISSX P, V6, P93
[9]
Stewart Barbra H., 1997, Pharmaceutical Research (New York), V14, pS671
[10]
PROTON-COTRANSPORT OF PRAVASTATIN ACROSS INTESTINAL BRUSH-BORDER MEMBRANE [J].
TAMAI, I ;
TAKANAGA, H ;
MAEDA, H ;
OGIHARA, T ;
YONEDA, M ;
TSUJI, A .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1727-1732